{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=59", "query": { "intervention": "Continuous Dose", "page": 59 }, "page_size": 10 }, "pagination": { "page": 59, "page_size": 10, "total_count": 5325, "total_pages": 533, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=60&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=58&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T15:25:15.866Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00283803", "title": "Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Exisulind", "type": "DRUG" }, { "name": "luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" }, { "name": "Antiandrogen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "MALE", "summary": "21 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2002-03-12", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283803" }, { "nct_id": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small-Cell Lung Cancer", "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Gocatamig", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Ifinatamab Deruxtecan (I-DXd)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 232, "start_date": "2020-12-14", "completion_date": "2028-01-28", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04471727" }, { "nct_id": "NCT01362374", "title": "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2011-07-11", "completion_date": "2020-10-16", "has_results": false, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 7, "location_summary": "San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362374" }, { "nct_id": "NCT05777174", "title": "Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Diseases", "Kidney Injury", "Kidney Failure" ], "interventions": [ { "name": "MB-102", "type": "DRUG" }, { "name": "MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "MediBeacon", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2023-03-20", "completion_date": "2024-04-15", "has_results": true, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 5, "location_summary": "Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Austin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05777174" }, { "nct_id": "NCT05419518", "title": "Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasm Metastases", "Metastases, Neoplasm" ], "interventions": [ { "name": "EXTERNAL BEAM RADIATION", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2023-03-16", "completion_date": "2027-04-01", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 7, "location_summary": "Hamilton, New Jersey • Lakewood, New Jersey • Livingston, New Jersey + 3 more", "locations": [ { "city": "Hamilton", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05419518" }, { "nct_id": "NCT01152697", "title": "Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Patient Noncompliance" ], "interventions": [ { "name": "haloperidol decanoate", "type": "DRUG" }, { "name": "haloperidol", "type": "DRUG" }, { "name": "Customized Adherence Enhancement", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University Hospitals Cleveland Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-06", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-12-30", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01152697" }, { "nct_id": "NCT05037123", "title": "Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Postsurgical Pain" ], "interventions": [ { "name": "Continuous ketamine infusion", "type": "DRUG" }, { "name": "Ketamine + Saline", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 765, "start_date": "2022-01-04", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Chicago, Illinois + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chestnut Hill", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05037123" }, { "nct_id": "NCT06775041", "title": "Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hutchinson-Gilford Progeria Syndrome" ], "interventions": [ { "name": "Progerinin", "type": "DRUG" }, { "name": "Lonafarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PRG Science & Technology Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 10, "start_date": "2025-01-13", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06775041" }, { "nct_id": "NCT02147990", "title": "Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rociletinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 318, "start_date": "2014-06-16", "completion_date": "2019-08-27", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 41, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 36 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02147990" }, { "nct_id": "NCT02122913", "title": "A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors Harboring NTRK Fusion" ], "interventions": [ { "name": "Larotrectinib (Vitrakvi, BAY2757556)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2014-05-04", "completion_date": "2021-04-09", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-11-10T15:25:15.866Z", "location_count": 8, "location_summary": "Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122913" } ] }